Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Indivior ( (GB:INDV) ) just unveiled an announcement.
Indivior PLC announced it will release its Q4 and full-year 2024 financial results on February 20, 2025. The company’s CEO, Mark Crossley, along with other leadership members, will present the results via a live webcast. This announcement provides stakeholders with an opportunity to gain insights into Indivior’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
More about Indivior
Indivior is a global pharmaceutical company focused on developing medications for substance use disorders (SUD). Headquartered in Richmond, VA, the company aims to transform SUD from a global crisis into a recognized chronic disease through a comprehensive portfolio of opioid use disorder (OUD) treatments and a strong pipeline of product candidates. Indivior operates in over 30 countries and employs more than 1,000 individuals worldwide.
YTD Price Performance: -6.49%
Average Trading Volume: 278,042
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.19B
See more data about INDV stock on TipRanks’ Stock Analysis page.
